Viscosupplementation Market

TABLE OF CONTENTS

1 INTRODUCTION
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
           1.2.2 MARKETS COVERED
           1.2.3 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY
    1.4 LIMITATIONS
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
    2.1 RESEARCH DATA
    2.2 RESEARCH APPROACH
           2.2.1 SECONDARY DATA
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                    2.2.2.1 Key data from primary sources
                    2.2.2.2 Key industry insights
    2.3 MARKET SIZE ESTIMATION
           2.3.1 BOTTOM-UP APPROACH
           2.3.2 TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN & DATA TRIANGULATION
    2.5 ASSUMPTIONS FOR THE STUDY
    2.6 MARKET SHARE ANALYSIS
    2.7 GROWTH RATE ASSUMPTIONS
    2.8 LIMITATIONS
    2.9 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           5.2.1 DRIVERS
                    5.2.1.1 Increasing prevalence of osteoarthritis among geriatric population
                    5.2.1.2 New product development
                    5.2.1.3 High investments in R&D
                    5.2.1.4 increasing number of sports injuries
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of products
                    5.2.2.2 Side effects associated with hyaluronic acid cycles
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Innovations in intra-articular single-injection viscosupplements
                    5.2.3.2 Safe and effective intra-articular hyaluronic acid
           5.2.4 CHALLENGES
                    5.2.4.1 Reduced pain relief due to poor absorption of viscosupplementation
                    5.2.4.2 Strict government policies for the use of viscosupplementation
    5.3 TECHNOLOGY ANALYSIS
    5.4 VALUE CHAIN ANALYSIS
    5.5 SUPPLY CHAIN ANALYSIS
    5.6 ECOSYSTEM ANALYSIS 
    5.7 PORTER’S FIVE FORCES ANALYSIS

6 GLOBAL VISCOSUPPLEMENTATION MARKET, BY PRODUCT (USD MILLION)
    6.1 INTRODUCTION
    6.2 SINGLE INJECTION
    6.3 THREE INJECTION
    6.4 FIVE INJECTION

7 GLOBAL VISCOSUPPLEMENTATION MARKET, BY APPLICATION (USD MILLIONS)
    7.1 INTRODUCTION
    7.2 KNEE OSTEOARTHRITIS
    7.3 HIP OSTEOARTHRITIS
    7.4 SHOULDER OSTEOARTHRITIS
    7.5 OTHER APPLICATIONS

8 GLOBAL VISCOSUPPLEMENTATION MARKET, BY SOURCE (USD MILLIONS)
    8.1 INTRODUCTION
    8.2 ANIMAL SOURCE
    8.3 NON-ANIMAL SOURCE

9 GLOBAL VISCOSUPPLEMENTATION MARKET, BY END USER
    9.1 INTRODUCTION
    9.2 HOSPITALS
    9.3 ORTHOPEDIC CLINICS/AMBULATORY SURGICAL CENTERS (ASCS)
    9.4 RETAIL PHARMACIES
    9.5 ONLINE PHARMACIES

10 GLOBAL VISCOSUPPLEMENTATION MARKET, BY REGION
     10.1 INTRODUCTION
     10.2 NORTH AMERICA
             10.2.1 US
             10.2.2 CANADA
     10.3 EUROPE
             10.3.1 GERMANY
             10.3.2 UK
             10.3.3 FRANCE
             10.3.4 ITALY
             10.3.5 SPAIN
             10.3.6 REST OF EUROPE
     10.4 ASIA PACIFIC
             10.4.1 CHINA
             10.4.2 JAPAN
             10.4.3 INDIA
             10.4.4 AUSTRALIA
             10.4.5 SOUTH KOREA
             10.4.6 REST OF ASIA PACIFIC
     10.5 LATIN AMERICA
             10.5.1 BRAZIL
             10.5.2 MEXICO
             10.5.3 REST OF LATIN AMERICA
     10.6 MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE
     11.1 OVERVIEW
     11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
     11.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
     11.4 MARKET SHARE ANALYSIS
     11.5 COMPANY EVALUATION QUADRANT
     11.6 COMPA4NY EVALUATION QUADRANT FOR STARTUPS/SMES (2020)
     11.7 COMPETITIVE BENCHMARKING
     11.8 COMPETITIVE SCENARIO

12 COMPANY PROFILES
     12.1 KEY PLAYERS
(Business Overview, Products and Services Offered, Recent Developments, MnM View, Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) *
             12.1.1 SANOFI
             12.1.2 ANIKA THERAPEUTICS, INC.
             12.1.3 SEIKAGAKU CORPORATION
             12.1.4 ZIMMER BIOMET
             12.1.5 SMITH & NEPHEW PLC
             12.1.6 FERRING PHARMACEUTICAL B.V.
             12.1.7 LIFECORE BIOMEDICAL, LLC (LANDEC)
             12.1.8 LG LIFE SCIENCES LTD.
             12.1.9 FIDIA FARMACEUTICI S.P.A
             12.1.10 F.HOFFMANN-LA ROCHE LTD.
             12.1.11 CHUGAI PHARMACEUTICAL CO., LTD.
             12.1.12 ORTHOGENRX INC.
             12.1.13 MYLAN N.V.
             12.1.14 APTISSEN
             12.1.15 AVANOS MEDICAL, INC.
             12.1.16 BIOVENTUS
             12.1.17 MIRAVO HEALTHCARE
             12.1.18 LABRHA INTERNATIONAL
             12.1.19 WELLCHEM PHARMACEUTICALS PTE LTD.
             12.1.20 JOHNSON & JOHNSON SERVICES, INC.

*Details on Business Overview, Products and Services Offered, Recent Developments, MnM View, Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats might not be captured in case of unlisted companies.

13 APPENDIX
     13.1 INDUSTRY INSIGHTS
     13.2 DISCUSSION GUIDE
     13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL
     13.4 AVAILABLE CUSTOMIZATIONS
     13.5 RELATED REPORTS
     13.6 AUTHOR DETAILS